Aquatic Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Aquatic Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$69.8K	Buy	+1,864	New	+$69.3K	﹤0.01%	1132
2025 Q1	–	Sell	-27,712	Closed	-$1.42M	–	1318
2024 Q4	$1.42M	Buy	+27,712	New	+$1.55M	0.04%	455
2024 Q2	–	Sell	-7,100	Closed	-$332K	–	1296
2024 Q1	$332K	Buy	+7,100	New	+$278K	0.01%	645
2023 Q3	–	Sell	-3,900	Closed	-$70K	–	1311
2023 Q2	$70K	Buy	+3,900	New	+$77.8K	﹤0.01%	928
2022 Q2	–	Sell	-200	Closed	-$4K	–	1260
2022 Q1	$4K	Sell	200 -3,300	-94%	-$66.8K	0.01%	857
2021 Q4	$99K	Buy	+3,500	New	+$86.3K	0.19%	132

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aquatic Capital Management's CRNX Position: Q2 2026 in Review

Aquatic Capital Management opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 1,864 shares worth $69.8K. The stake represents ﹤0.01% of the portfolio and ranks #1132 among its holdings. This is a return to the name: Aquatic Capital Management previously reported a position in CRNX as recently as Q4 2024.

Aquatic Capital Management first reported a position in CRNX in Q4 2021 and has held it in 6 quarters since. The position peaked at $1.42M in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Aquatic Capital Management held 1,864 shares of Crinetics Pharmaceuticals worth $69.8K as of Q2 2026.
Crinetics Pharmaceuticals was a new Aquatic Capital Management position in Q2 2026.
Crinetics Pharmaceuticals made up ﹤0.01% of Aquatic Capital Management's portfolio in Q2 2026, its #1132 holding.
Aquatic Capital Management first reported a position in Crinetics Pharmaceuticals in Q4 2021 and has held it in 6 quarters since.
Aquatic Capital Management's Crinetics Pharmaceuticals position peaked at $1.42M in Q4 2024.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.